Key Highlights
- Eleven sites are open for enrollment in the TakeAim CLL study of emavusertib plus zanubrutinib, with ten patients consented as of July 22, 2026 and dosing guidance reaffirmed for end of July.
- Updated TakeAim Lymphoma data disclosed July 22, 2026 showed a 100% response rate among five evaluable BTK inhibitor-naive patients and 33% among 30 evaluable BTK inhibitor-experienced patients.
- Curis reported a $24.2 million net loss for the quarter ended March 31, 2026, no revenue, and cash of $15.0 million, with a going-concern disclosure in its Form 10-Q.
- Stockholders approved a reverse split of 1-for-5 to 1-for-25 on June 25, 2026 for a Nasdaq bid-price deficiency; ratio and effective date remained unannounced as of the research date.
Curis, Inc. (NASDAQ:CRIS) has activated eleven clinical sites for its Phase 2 TakeAim CLL study and, as of July 22, 2026, had consented ten patients toward a dosing readout due by end of July. The Lexington, Massachusetts biotech also disclosed encouraging lymphoma data, but carries a going-concern warning, a Nasdaq listing deficiency and a reverse split still awaiting a ratio.
A Clinical-Stage Story Racing Its Own Cash Clock
Curis's June 26, 2026 disclosure that eleven sites had opened for enrollment in the Phase 2 TakeAim CLL study, followed by updates on July 6 and July 22 that patient consent had climbed from six to ten, gave the stock a steady drumbeat of news ahead of a dosing readout due by end of July 2026.
Curis is, in practical terms, a single-asset company. Its legacy product, Erivedge, no longer generates revenue after Curis sold that royalty stream in November 2025. Nearly everything now rides on emavusertib, an oral small molecule inhibiting IRAK4 and FLT3, in chronic lymphocytic leukemia (CLL) and primary CNS lymphoma (PCNSL), where Curis pairs it with approved BTK inhibitors.
From a Hedgehog-Pathway Pioneer to a Single-Asset IRAK4 Story
Curis traces its royalty history to a 2003 deal licensing its Hedgehog pathway antagonist technology to Genentech, which developed it into Erivedge for advanced basal cell carcinoma, marketed by Genentech in the U.S. and Roche elsewhere. In November 2025, Curis sold those royalty rights to TPC Investments Royalty LLC, managed by Oberland Capital Management, and per its 10-Q is "no longer entitled to revenues under the Genentech License Agreement."
Today's Curis is built around a 2015 collaboration with Aurigene Discovery Technologies Limited, giving it an exclusive license to emavusertib (CA-4948), under which it still owes Aurigene up to $42.5 million per program in milestones. Emavusertib holds FDA Orphan Drug Designation for PCNSL, AML and MDS, and EC designation for PCNSL.
Curis (CRIS) Speeds Toward Its TakeAim CLL Dosing Readout
The TakeAim CLL study (CA-4948-203, NCT07271667) is an open-label Phase 2 trial pairing emavusertib with the BTK inhibitor zanubrutinib in CLL patients in partial response, with residual disease confirmed by the clonoSEQ assay, after at least 12 months on zanubrutinib alone. BTK inhibitors block only the B-cell receptor pathway driving CLL; emavusertib blocks the parallel toll-like receptor pathway, so the combination aims to more fully suppress the NF-kB signaling sustaining the disease.
Enrollment has moved faster than initially guided. After the June 26, 2026 announcement of eleven active sites, Curis said on July 6 that it had consented its first six patients, rising to ten by July 22. CEO James Dentzer credited "strong interest among clinical sites and key opinion leaders." Curis has reaffirmed that the first five patients will be dosed by end of July 2026, and widened its year-end data guidance from five patients to five-to-ten, expected in December 2026.
Wider Losses and a Larger Share Count in the March Quarter
For the quarter ended March 31, 2026, Curis reported a net loss of $24.2 million, versus $10.6 million a year earlier. Loss per share held at $1.25 in both periods because weighted-average shares outstanding rose to roughly 19.4 million from 8.5 million. R&D expense fell to $6.4 million from $8.5 million on lower employee and manufacturing costs; G&A rose to $5.1 million from $4.0 million on costs tied to a January 2026 financing. Other expense swelled to $12.7 million from $0.5 million on a non-cash warrant-liability fair-value change.
Erivedge Royalties Are Gone; a PIPE Financing Buys Time
There was no revenue in the March 2026 quarter, versus $2.4 million a year earlier from Erivedge royalties, now eliminated. Cash stood at $15.0 million as of March 31, 2026, up from $5.1 million at year-end 2025, after a January 9, 2026 private placement with initial gross proceeds of about $20.2 million and potential total proceeds up to $80.8 million through three warrant series priced at $0.75 per share. That cash, plus up to $20.2 million more if holders exercise Series B warrants once dosing of the fifth CLL patient is announced, "should enable the Company's planned operations into the second half of 2027," Curis said. Even so, the 10-Q discloses conditions that "raise substantial doubt" about its ability to continue as a going concern absent further financing.
PCNSL Data, CLL Enrollment and the AML Legacy Program
The TakeAim Lymphoma study (CA-4948-101, NCT03328078) pairs emavusertib with ibrutinib in relapsed or refractory PCNSL. On July 22, 2026, Curis disclosed updated data showing a 100% response rate among five evaluable BTK inhibitor-naive patients and 86% across all seven such patients, up from 71% as of May 1, 2025. Among BTK inhibitor-experienced patients, the rate was 33% in 30 evaluable patients versus 27% previously. Curis said 2025 meetings with the FDA and EMA indicated the study could support accelerated approval in the U.S. and conditional marketing authorization in Europe. Its AML and MDS studies are "substantially complete," pending further funding. That program carries history: the FDA placed a partial clinical hold on it April 4, 2022, allowed partial resumption that August, and fully lifted the hold July 6, 2023, setting a 300 mg twice-daily recommended dose.
Going-Concern Language, a Nasdaq Deficiency and a Pending Reverse Split
Curis's 10-Q lists Nasdaq non-compliance, tied to the minimum bid price rule, among its principal risks. At a June 25, 2026 special meeting, stockholders approved a reverse split of between 1-for-5 and 1-for-25, ratio and timing left to board discretion; neither had been announced as of this writing. Layered on the listing issue is the going-concern disclosure, plus reliance on the Series B warrant exercise tied to the CLL dosing milestone. Both TakeAim programs remain early-stage, PCNSL samples are small, and the FDA's past partial hold on the AML program shows regulatory setbacks are not merely theoretical here.
Outlook
The bull case rests on emavusertib delivering deeper, more durable responses than BTK inhibitors alone, potentially supporting accelerated pathways in indications with real unmet need, particularly BTK inhibitor-experienced PCNSL patients who have no approved options. The base case: Curis keeps hitting enrollment and data milestones on roughly its guided cadence while leaning on financing and warrant proceeds to fund operations into the second half of 2027. The downside case involves slower CLL dosing, disappointing PCNSL durability data, or a financing environment that blocks warrant proceeds, which Curis's filings acknowledge would force delays or cutbacks.
Conclusion
Curis, Inc. (CRIS) has generated real operational momentum in its TakeAim CLL and TakeAim Lymphoma programs, activating eleven trial sites, accelerating patient consent, and reporting improved PCNSL response rates. Whether that translates into durable progress depends on the CLL dosing readout due by end of July and the December 2026 data update, measured against a cash position Curis says will not last twelve months without more financing.
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.






Please wait processing your request...